Makers of biosimilars have targeted a few of the top-selling autoimmune drugs. Get ready for some of the highest-stakes pricing and access skirmishes in recent pharma history.
While investments in investigational lupus agents appear to be heating up, late-stage clinical failure continues to be a major hurdle to market entry.
AbbVie's Humira tops the list, according to data compiled by EvaluatePharma.
Here you'll find everything you need to know from MM&M's April 2017 issue, including our DTC report, our deep dive into respiratory drugs, and more.
How are pharma, clinical, and startup execs addressing some of the biggest challenges facing their businesses today?
For the second year, MM&M is honoring 16 of the most-senior women in the healthcare industry.
A tool kit of pharma case studies and advice for healthcare brands in making behavioral science a foundational part of a marketing strategy.
MM&M honors 40 upstarts and veteran innovation gurus.
For the first time MM&M honors a group of 10 agency execs.
A WebMD survey finds that patients are more engaged when they share their own health with their doctors.
We had SERMO, a social network for physicians, ask about 1,700 physicians what they have to say about the impact of DTC on patient care and choices. Note: It's not pretty.
Drugmakers again spent more on DTC advertising in 2016 than the year before.
Pharma spent more than $4 billion on TV ads last year. Empowered patient communities weren't impressed. Has DTC on TV reached its moment of reckoning?
The top three most advertised brands in 2016 were Gilead Sciences' Harvoni, Eli Lilly's Trulicity, and J&J's Invokana.
Five highly placed insiders in a range of roles and therapeutic categories share secrets to their success and advice that served them well along the way.
Here you'll find everything you need to know from MM&M's March 2017 issue, including our healthcare marketers trend report, our deep dive into orphan drugs, and more.
Seven execs from A-list agencies weigh in on talent acquisition and retention.
While still the top-selling respiratory drug, GSK's Advair is facing growing competition from BI's Spiriva and Roche's Xolair.
An investigative agent in the Novartis asthma pipeline could give biologics a run for their money.
Biologics prompt asthma marketers to catch their collective breath as innovation has resulted in a rise of payer blockades and sky-high prices
Here you'll find everything you need to know from MM&M's February 2017 issue, including our payer state of the union, social media spotlight, and more.
There are also issues surrounding privacy and legitimacy. According to one expert's research, very few physicians use social media for professional purposes.
About 30% of patients are more likely to fill a prescription after being exposed to healthcare ads at the point of care, according to Kantar Media.
He describes his current charge as "transforming a more creative occupation into a science."
Guidemark Health COO Sophy Regelous shares her perspective on the 2017 MM&M/Guidemark Health Healthcare Marketers Report.
This according to the 172 healthcare marketing executives who participated in the 2017 MM&M/Guidemark Health Healthcare Marketers Trend Report.
Here you'll find everything you need to know from MM&M's January 2017 issue, including our health-tech preview, a deep dive into data science, and report on digital innovation from Japanese drugmakers.
A loaded hemophilia A drug market is an indication patients in and around it are well-served, but that hasn't stopped contenders such as Roche's emicizumab.
Teva Pharmaceutical Industries' Copaxone is by far the top-selling drug, bringing in $3.2 billion in U.S. sales in 2015.
When discussing the nation's ability to stomach orphan drug costs, an analyst has called the price tag "the straw that breaks the camel's back."
Each of the approaches is valid and more ambitious than a great majority of the campaigns that preceded them.
The Kim Kardashian debacle aside, what makes the platform so potentially valuable to pharma and healthcare marketers is its visual story-telling capability.
One pharmacy director would like to see a lot more comparative data about new therapies.
But have pharma and payers learned enough from earlier pilots to make modern risk-sharing deals work?
He played a leading role during Torre Lazur's glory era as "the launch agency." Now he is being inducted into the Medical Advertising Hall of Fame.
The founder of Pacific Communications shares the details of his career as he is inducted into the Medical Advertising Hall of Fame.
Type 2 diabetes has been hogging health headlines lately — and for good reason. But the incidence of type 1 diabetes is also on the rise.
Sanofi's Lantus is the top-selling product with its Lantus franchise. Merck's Januvia and Novo Nordisk's Victoza round out the top 3.
That may take a "focus on brand building that goes beyond 'ask your doctor if this drug is right for you.'"
Nobody knows what the future holds for the Affordable Care Act under the Trump administration and an emboldened Republican Congress.
"In Australia, we are the healthcare industry," he says.
Physicians do not like EHRs. That much is clear. But the vast majority have to use electronic record systems on a daily basis. What can pharma do to better give doctors what they want?
The top-selling heart drug is Merck's Zetia, which is expected to bring in about $1.68 billion in sales in 2016.
Despite their blockbuster status and distinction as the world's most widely prescribed class of drugs, statins may not be the best option for all patients with elevated low density lipoprotein (LDL) cholesterol levels.
The first two PCSK9s landed with a thud. What does their disappointing launch say about the need for marketers of CV drugs to get their pricing houses in order?
Otsuka, Astellas, Takeda, and Daiichi Sankyo share a degree of adventurousness and forward-mindedness in the digital realm.
When his mother suffered from ovarian cancer a decade ago, Robert Herjavec found himself frustrated by the quality of care she received.
The first step is to seek leadership support, she says.
The internet strongly agrees there's an artificial intelligence revolution going on, and it's come to pharma marketing.
Data scientists are a new kind of insight and analytics professional showing up in the biopharma ranks.
Here you'll find everything you need to know from MM&M's December 2016 issue, including our policy outlook for pharma in a Republican-led White House and Congress and the exclusive pipeline report.
Here's a look at 100 experimental therapies in late-stage clinical trials.
More barriers separate doctors and patients than ever before, from rising costs and time constraints to electronic health records and smartphones.
Specialty pharma ace Umer Raffat, a senior analyst at Evercore ISI, shares his 2016 postmortem and a few quick-hit predictions for 2017.
If Trump decides to go after pharma, politicians aren't likely to receive too many "How can you do this? Think about the children!" notes.
How pharma distributes information to doctors is changing as rapidly as how doctors prefer to receive and process such information
With lawmakers, patients, and physicians crying foul over pricing, drugmakers are trying to shift the narrative — with mixed results. Can a new focus on storytelling help?
As digital-health funding increases, here's how VR, nanotechnology, and 3D printing could potentially improve the value of healthcare.
Tech companies and Bernie Sanders have found the millennial audience easy to crack. Organizations in and around healthcare? Not so much.
MM&M and PRWeek editors convened to select 50 battle-tested pros who are changing the healthcare game. Find out if you made the list.
Here you'll find everything you need to know from MM&M's 50th anniversary issue, including the story behind Viagra, the death of tchotchkes, and much more.
The experimental therapy is positioned to fill a market gap in primary progressive multiple sclerosis.
MS drugs top the list, led by Teva's Copaxone, Biogen's Tecfida and Avonex, and Novartis' Gilenya.
The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.
Millian, a former Sanofi and Merck executive, on marketing new therapies in the MS market.
The chief creative officer at Carling Communications talks about how she learned that the best leaders are only as good as the performance of their team.
Ad pushes behind brands like Gilead Sciences' hepatitis-C pill Harvoni and Allergan's IBS drug Viberzi buoyed med-surg outlays for the first six months of 2016. Cancer drugs once again were the hottest category.
Here, you'll find everything you need to know about MM&M's 2016 Career and Salary Survey, including data on salaries and agency employment trends.
The agency's ambitions were fueled in part by external criticism. The barbs that stung most sharply were ones suggesting a certain indifference on the FDA's part.
When drug costs started to soar, PBMs turned to formulary exclusions — and the industry is still feeling the pinch.
Given its modern-day ubiquity, it's easy to forget that pharma DTC didn't exist until the 1980s rolled around.
The inside story on a campaign for the ages, as told by the individuals who worked on it.
Did you know that Norman Rockwell was a medical illustrator for Merck?
For some people in the industry ecosystem, the appeal of promo knickknacks endures.
And why the stories behind thalidomide, Naprosyn, AZT, cardiology stents, and Zaltrap still resonate.
The vice president of audience development talks about her days in the dot-com world and how struggling in a new role shaped her career.
They share their insights, secrets, worries, and everything else in between.
Hint: it pays to be an EVP.
"It's easy to 'fill open positions,'" Marchese says. "We've banned that phrase. If you do that, you're just checking boxes on a list."
Execs say that career prospects are better than ever. Yet data from MM&M's annual Career and Salary Survey reveals a decline in growth.
The intersection of data, technology, and medicine is rapidly changing how doctors practice, drug companies market, and patients engage with the healthcare system.
The availability of online medical information is changing the way doctors share and receive information — both among themselves and with their patients.
Diabetes is one of the most stubborn conditions to treat effectively. Drugmakers are turning to machine learning, online coaching, and gamification.
Will this payer pressure pose an existential threat to co-pay cards even though patients love them?
Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?
Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.